$AMLX

Amylyx Pharmaceuticals, Inc. (AMLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 amlx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results • Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypog

Biotech and healthcare stocks hit 52-week highs on July 27, 2026. Dyne Therapeutics (DYN) rose over 5% to $26.12 after FDA accepted its Z-Rostudirsen BLA; it raised $431m. Sonida Senior Living (SNDA) reached $44.38 after its CHP acquisition. Silence Therapeutics (SLN) hit $12.19. Amylyx (AMLX) rose to $19.60. Labcorp (LH) climbed to $301.7 after launching a genetic testing platform; Q1 revenue was $3.54b and 2026 revenue guidance $14.65b-$14.80b.

Mazzariello Gina (Chief Legal Officer) sold 30,000 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at an average of $17.96 ($17.61–$18.32, $0.54M total) across 2 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.

Amylyx Pharmaceuticals (NASDAQ: AMLX) said it will present first-in-human, dose-ranging Phase 1 LUMINA trial data for AMX0114 at ENCALS 2026 (June 24-26, Madrid). In Cohort 1 (12.5 mg; n=12), the company reported no drug-related serious adverse events or serious neurological adverse events, and biomarker levels (SBDP-145, NfL, pNFH) stayed near baseline. Cohort 2 (25 mg) is fully enrolled; Cohort 3 (50 mg) is enrolling.

BNN Bloomberg cites Citi’s Geoff Meacham saying biotech is recovering as capital markets improve and interest rates fall. He highlights Eli Lilly’s oral GLP-1 orforglipron and pipeline expansion beyond obesity/diabetes; Veradermics after a Phase 3 male-pattern hair loss result with a female trial ongoing; and Amylyx’s Phase 3 avexitide for post-bariatric uncontrolled hypoglycemia, with data next quarter.

Firestone Karen purchased 3,800 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at $13.51 on 2026-05-21.

MarketBeat says Amylyx’s pipeline matters for investors, highlighting AMX0035 for Wolfram Syndrome in Phase 2 HELIOS. The article cites positive Week 24 and Week 48 results and plans to share Week 96 data later in 2026; it estimates a global market of 15,000–30,000 patients. It also notes AMX0114 for ALS, with Cohort 2 enrollment completed in March 2026 and early Cohort 1 biomarker data expected in June 2026, plus FDA Fast Track. MarketBeat’s consensus price target is $23.

Amylyx Pharmaceuticals reported narrowed net losses for Q4 and full-year 2025, alongside new shelf registrations for various securities. These developments suggest increased financial flexibility for future growth, though potential shareholder dilution remains a concern. The company's investment narrative now focuses on advancing its pipeline while managing capital needs.

Stifel analyst James Condulis initiated coverage on Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) with a Buy rating and a $21 price target. This article also highlights three other significant analyst initiations for Tuesday, including Goldman Sachs on Once Upon A Farm PBC (NYSE: OFRM), Morgan Stanley on Agomab Therapeutics NV (NASDAQ: AGMB), and Stifel on SpyGlass Pharma, Inc. (NASDAQ: SGP), all with bullish ratings and specific price targets.

Amylyx Pharmaceuticals Co-Chief Executive Officer, Joshua B Cohen, sold 138,167 shares of AMLX for approximately $1.9 million to cover option costs and tax obligations. This sale significantly exceeded his historical median sell size, reducing his direct ownership by 3.93%. The company, which focuses on neurodegenerative diseases like ALS and endocrine conditions, has seen its stock perform well, though it is currently under investigation for alleged breaches of fiduciary duties.